[go: up one dir, main page]

MA40111A1 - Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 - Google Patents

Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Info

Publication number
MA40111A1
MA40111A1 MA40111A MA40111A MA40111A1 MA 40111 A1 MA40111 A1 MA 40111A1 MA 40111 A MA40111 A MA 40111A MA 40111 A MA40111 A MA 40111A MA 40111 A1 MA40111 A1 MA 40111A1
Authority
MA
Morocco
Prior art keywords
protein
tetrahydronaphthalene
derivatives
compounds
inhibiting mcl
Prior art date
Application number
MA40111A
Other languages
English (en)
Other versions
MA40111B1 (fr
Inventor
Sean P Brown
Yunxiao Li
Mike Elias Lizarzaburu
Brian S Lucas
Nick A Paras
Joshua Taygerly
Marc Vimolratana
Xianghong Wang
Ming Yu
Manuel Zancanella
Liusheng Zhu
Buenrostro Ana Gonzalez
Zhihong Li
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA40111A1 publication Critical patent/MA40111A1/fr
Publication of MA40111B1 publication Critical patent/MA40111B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des inhibiteurs de la protéine de la leucémie myéloïde 1 (mcl-1), leurs procédés de préparation, des compositions pharmaceutiques associées, et leurs méthodes d'utilisation. L'invention concerne, par exemple, de composés de formule (i) et des sels pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions comprenant ces composés. Les composés et les compositions de l'invention peuvent être utilisés, par exemple, dans le traitement de maladies ou affections telles que le cancer.
MA40111A 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 MA40111B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043929P 2014-08-29 2014-08-29
PCT/US2015/047472 WO2016033486A1 (fr) 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Publications (2)

Publication Number Publication Date
MA40111A1 true MA40111A1 (fr) 2018-06-29
MA40111B1 MA40111B1 (fr) 2018-12-31

Family

ID=54238507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40111A MA40111B1 (fr) 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Country Status (41)

Country Link
US (7) US9562061B2 (fr)
EP (2) EP3424931B1 (fr)
JP (1) JP6502479B2 (fr)
KR (1) KR102466351B1 (fr)
CN (1) CN107001387B (fr)
AP (1) AP2017009827A0 (fr)
AR (1) AR101729A1 (fr)
AU (1) AU2015308735B2 (fr)
BR (1) BR112017004209B1 (fr)
CA (1) CA2959615C (fr)
CL (1) CL2017000469A1 (fr)
CO (1) CO2017002998A2 (fr)
CR (1) CR20170116A (fr)
CY (1) CY1121195T1 (fr)
DK (1) DK3186259T3 (fr)
EA (1) EA031223B1 (fr)
ES (2) ES2777478T3 (fr)
HR (1) HRP20190053T1 (fr)
HU (1) HUE041806T2 (fr)
IL (2) IL250843B (fr)
JO (1) JO3474B1 (fr)
LT (1) LT3186259T (fr)
MA (1) MA40111B1 (fr)
ME (1) ME03313B (fr)
MX (1) MX379155B (fr)
MY (1) MY176235A (fr)
PE (1) PE20170892A1 (fr)
PH (1) PH12017500367B1 (fr)
PL (1) PL3186259T3 (fr)
PT (1) PT3186259T (fr)
RS (1) RS58276B1 (fr)
SG (1) SG11201701525WA (fr)
SI (1) SI3186259T1 (fr)
SM (1) SMT201900048T1 (fr)
TN (1) TN2017000067A1 (fr)
TR (1) TR201901312T4 (fr)
TW (1) TWI676628B (fr)
UA (1) UA118233C2 (fr)
UY (1) UY36285A (fr)
WO (1) WO2016033486A1 (fr)
ZA (2) ZA201701763B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
EP3454862B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
WO2018015526A1 (fr) 2016-07-22 2018-01-25 Les Laboratoires Servier Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019035927A1 (fr) * 2017-08-15 2019-02-21 Abbvie Inc. Inhibiteurs de mcl-1 macrocyclique et procédés d'utilisation
EP3652184A4 (fr) * 2017-08-15 2020-05-20 AbbVie Inc. Inhibiteurs macrocycliques de mcl-1 et méthodes d'utilisation
EP3668878B1 (fr) 2017-08-18 2025-05-21 Amgen Inc. Composés inhibant la protéine mcl-1
MA50033A (fr) 2017-08-29 2020-07-08 Amgen Inc Composés macrocycliques permettant d'inhiber la protéine mcl-1
US11274105B2 (en) 2018-03-05 2022-03-15 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists
PE20210004A1 (es) * 2018-05-14 2021-01-05 Gilead Sciences Inc Inhibidores de mcl-1
WO2020097577A1 (fr) * 2018-11-09 2020-05-14 Prelude Therapeutics, Incorporated Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
TWI745836B (zh) * 2019-01-18 2021-11-11 大陸商蘇州亞盛藥業有限公司 作為mcl-1抑製劑的大螺環醚
US20230092679A1 (en) 2019-05-20 2023-03-23 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
BR112021025732A2 (pt) * 2019-06-21 2022-04-12 Janssen Pharmaceutica Nv Inibidores macrocíclicos de mcl-1
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
ES2987630T3 (es) 2019-07-09 2024-11-15 Janssen Pharmaceutica Nv Derivados de espirociclos macrocíclicos como inhibidores de MCL-1
EP3771469A1 (fr) * 2019-07-30 2021-02-03 Amgen, Inc Formulations et dosages pour l'administration d'un composé inhibant la protéine mcl1
WO2021047616A1 (fr) * 2019-09-12 2021-03-18 苏州亚盛药业有限公司 Composé spiro à base d'heptane hétérocyclique d'oxynitrure, intermédiaire et procédé de préparation associé
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
US11739074B2 (en) * 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020391106B2 (en) 2019-11-26 2024-03-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
WO2021165370A1 (fr) * 2020-02-21 2021-08-26 Janssen Pharmaceutica Nv Dérivés d'indole macrocycliques en tant qu'inhibiteurs de mcl-1
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化
US20230212191A1 (en) * 2020-04-16 2023-07-06 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
KR20230006891A (ko) 2020-05-01 2023-01-11 길리애드 사이언시즈, 인코포레이티드 Cd73를 억제하는 2,4-다이옥소피리미딘 화합물
CN115515931B (zh) * 2020-05-06 2024-10-18 安进公司 磺酰胺中间体的合成
CN115461332A (zh) * 2020-05-06 2022-12-09 安进公司 乙烯醇中间体的合成
TWI867217B (zh) * 2020-05-06 2024-12-21 美商安進公司 乙烯基環丁基中間體之合成
KR20230006550A (ko) 2020-05-06 2023-01-10 암젠 인크 비닐 보호된 알코올 중간체의 합성
TWI827924B (zh) 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
US20230219906A1 (en) 2020-06-10 2023-07-13 Janssen Pharmaceutica Nv Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
EP4208467A1 (fr) 2020-09-03 2023-07-12 Amgen Inc. Désymétrisation de diols par substitution aromatique nucléophile
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
CA3201943A1 (fr) 2020-11-19 2022-05-27 Gilead Sciences, Inc. Procedes et intermediaires pour la preparation d'inhibiteurs de mcl1 macrocycliques
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
US20240002400A1 (en) * 2020-11-25 2024-01-04 Amgen Inc. Enantioselective alkenylation of aldehydes
EP4008324A1 (fr) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer
EP4255409A1 (fr) 2020-12-07 2023-10-11 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
CA3200704A1 (fr) 2020-12-17 2023-06-23 Meng-Yang HSIAO 3-fluoro-but-3-enamides ramifies macrocycliques utilises comme inhibiteurs de mcl-1
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
BR112023020877A2 (pt) 2021-04-26 2023-12-12 Janssen Pharmaceutica Nv 2-aliltetra-hidrofuranos macrocíclicos como inibidores de mcl-1
EP4334325A1 (fr) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Inhibiteurs de ras pour le traitement du cancer
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2022261310A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des conjugués anti-corps-médicament
EP4351564A1 (fr) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des agents anticancéreux
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
EP4359411A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
JP2024544570A (ja) 2021-11-16 2024-12-03 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１阻害剤としての大環状２－アミノ－ブト－３－エナミド
WO2023107956A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et 5t4
WO2023107954A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Anticorps ciblant 5t4 et leurs utilisations
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415A1 (fr) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CA3254998A1 (fr) 2022-04-05 2023-10-12 Amgen Inc. Formes de sel et solvates d'antagonistes de mci-1
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
AU2023250874A1 (en) 2022-04-05 2024-10-10 Amgen Inc. Amorphous and crystalline forms of mci-1 antagonists
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023225359A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament de composés anti-cancéreux et procédés d'utilisation
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
WO2024064668A1 (fr) 2022-09-21 2024-03-28 Gilead Sciences, Inc. POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
WO2024220917A1 (fr) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
EP4516807A1 (fr) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions destinées à être utilisées dans un procédé de fourniture d'une greffe améliorée de cellules souches hématopoïétiques
WO2025054347A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Composés de modulation de kras g12d
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025111431A1 (fr) 2023-11-22 2025-05-30 Les Laboratoires Servier Conjugués anticorps-médicament anti-cd7 et leurs procédés d'utilisation
WO2025111450A1 (fr) 2023-11-22 2025-05-30 Les Laboratoires Servier Conjugués anticorps anti-cd74-médicament et leurs procédés d'utilisation
WO2025126157A1 (fr) 2023-12-15 2025-06-19 Advesya Domaines de liaison anti-il-1rap et conjugués anticorps-médicament associés
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (fr) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US7750004B2 (en) * 2005-07-07 2010-07-06 Abbott Laboratories Apoptosis promoters
JP5496877B2 (ja) 2007-04-16 2014-05-21 アッヴィ・インコーポレイテッド ７−置換インドールＭｃｌ−１阻害薬
AU2008281849B2 (en) * 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
WO2011022312A1 (fr) * 2009-08-20 2011-02-24 Merck Sharp & Dohme Corp. Dérivés d’éther de benzotriazole
IN2012DN02816A (fr) * 2009-10-08 2015-07-24 Sanford Burnham Med Res Inst
EP2528893B1 (fr) * 2010-01-29 2018-10-10 Dana-Farber Cancer Institute, Inc. Petites molécules pour la modulation de mcl-1 et procédés de modulation de la mort cellulaire, la division cellulaire, la différenciation cellulaire et procédés de traitement de troubles
US9486422B2 (en) 2011-10-06 2016-11-08 The Regents Of The University Of Michigan Small molecule inhibitors of Mcl-1 and the uses of thereof
ES2657649T3 (es) * 2012-03-29 2018-03-06 The Regents Of The University Of Michigan Inhibidores de Mcl-1 de molécula pequeña y sus usos
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein

Also Published As

Publication number Publication date
US12024529B2 (en) 2024-07-02
US20200062780A1 (en) 2020-02-27
CA2959615A1 (fr) 2016-03-03
CO2017002998A2 (es) 2017-07-19
PH12017500367A1 (en) 2017-07-10
PL3186259T3 (pl) 2019-04-30
EP3186259A1 (fr) 2017-07-05
DK3186259T3 (en) 2019-02-25
PH12017500367B1 (en) 2017-07-10
SI3186259T1 (sl) 2019-03-29
RS58276B1 (sr) 2019-03-29
BR112017004209B1 (pt) 2022-08-09
US10836779B2 (en) 2020-11-17
EA201790492A1 (ru) 2017-07-31
US10494381B2 (en) 2019-12-03
ZA201701763B (en) 2018-08-29
AR101729A1 (es) 2017-01-11
CR20170116A (es) 2017-04-28
MX379155B (es) 2025-03-11
HUE041806T2 (hu) 2019-05-28
US11685747B2 (en) 2023-06-27
EP3424931A3 (fr) 2019-02-20
MY176235A (en) 2020-07-24
US20160068545A1 (en) 2016-03-10
ES2777478T3 (es) 2020-08-05
TN2017000067A1 (en) 2018-07-04
US9562061B2 (en) 2017-02-07
CN107001387A (zh) 2017-08-01
CY1121195T1 (el) 2020-05-29
IL257942B (en) 2020-05-31
US10100063B2 (en) 2018-10-16
ES2706309T3 (es) 2019-03-28
JP6502479B2 (ja) 2019-04-17
HRP20190053T1 (hr) 2019-02-22
US20210040120A1 (en) 2021-02-11
CA2959615C (fr) 2023-01-17
IL257942A (en) 2018-05-31
EP3186259B1 (fr) 2018-12-19
JP2017525730A (ja) 2017-09-07
MX2017002656A (es) 2017-10-12
IL250843B (en) 2018-03-29
NZ729768A (en) 2021-06-25
US20190016736A1 (en) 2019-01-17
EP3424931B1 (fr) 2020-02-12
MA40111B1 (fr) 2018-12-31
AP2017009827A0 (en) 2017-03-31
KR102466351B1 (ko) 2022-11-10
EA031223B1 (ru) 2018-12-28
LT3186259T (lt) 2019-02-25
TWI676628B (zh) 2019-11-11
ZA201802865B (en) 2022-05-25
WO2016033486A1 (fr) 2016-03-03
US20170088560A1 (en) 2017-03-30
CL2017000469A1 (es) 2017-11-03
PE20170892A1 (es) 2017-07-12
KR20170043661A (ko) 2017-04-21
US20190023720A1 (en) 2019-01-24
PT3186259T (pt) 2019-02-06
UA118233C2 (uk) 2018-12-10
AU2015308735A1 (en) 2017-03-23
US11001598B2 (en) 2021-05-11
BR112017004209A2 (pt) 2018-07-31
TR201901312T4 (tr) 2019-02-21
IL250843A0 (en) 2017-04-30
US20230271981A1 (en) 2023-08-31
SMT201900048T1 (it) 2019-02-28
UY36285A (es) 2016-04-01
AU2015308735B2 (en) 2019-03-14
EP3424931A2 (fr) 2019-01-09
CN107001387B (zh) 2019-03-05
JO3474B1 (ar) 2020-07-05
SG11201701525WA (en) 2017-03-30
ME03313B (fr) 2019-10-20
TW201625645A (zh) 2016-07-16

Similar Documents

Publication Publication Date Title
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA39783B1 (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques